Table 2B. HRs for disease-specific death in OPSCC stratified by HPV status.
| |
HPV-positive OPSCC,
n=149 |
HPV-negative OPSCC,
n=121 |
||||
|---|---|---|---|---|---|---|
| Univariate HR (95% CI) | Multivariate HRa (95% CI) | P-value | Univariate HR (95% CI) | Multivariate HRa (95% CI) | P-value | |
|
Age | ||||||
| For each additional year |
1.00 (0.97–1.04) |
1.02 (0.98–1.06) |
0.28 |
1.02 (0.99–1.04) |
1.02 (0.99–1.05) |
0.19 |
|
Gender | ||||||
| Female | 1 | 1 | 1 | 1 | ||
| Male |
1.19 (0.50–2.81) |
0.74 (0.26–2.11) |
0.58 |
2.06 (1.06–4.02) |
1.70 (0.79–3.64) |
0.17 |
|
Smoking | ||||||
| Non/ex-smoker/current Smoker <10 pack-years | 1 | 1 | 1 | 1 | ||
| Current smoker >10 pack-years |
5.81 (2.38–14.16) |
5.80 (2.31–14.54) |
<0.001 |
1.37 (0.71–2.64) |
1.61 (0.82–3.16) |
0.17 |
|
Drinking | ||||||
| Non/ex-drinker | 1 | 1 | 1 | 1 | ||
| Current drinker |
0.63 (0.23–1.71) |
0.29 (0.08–1.04) |
0.06 |
0.68 (0.31–1.49) |
0.54 (0.22–1.28) |
0.16 |
|
Stage | ||||||
| Early (I/II) | 1 | — | — | 1 | — | — |
| Late (III/IV) |
1.93 (0.26–14.27) |
— |
— |
1.83 (0.99–3.37) |
— |
— |
|
T stage | ||||||
| T1/2 | 1 | 1 | 1 | 1 | ||
| T3/4 |
3.42 (1.61–7.28) |
3.04 (1.28–7.22) |
0.01 |
1.24 (0.71–2.17) |
0.98 (0.52–1.84) |
0.94 |
|
Nodal metastases | ||||||
| No | 1 | — | — | 1 | — | — |
| Yes |
1.65 (0.39–7.00) |
— |
— |
2.13 (1.19–3.79) |
— |
— |
|
N stage | ||||||
| N0–N2a | 1 | 1 | 1 | 1 | ||
| N2b–N3 |
2.29 (1.00–5.24) |
1.67 (0.67–4.14) |
0.27 |
2.06 (1.20–3.53) |
2.15 (1.14–4.06) |
0.02 |
|
Tumour grade | ||||||
| Well/moderately differentiated | 1 | 1 | 1 | 1 | ||
| Poorly differentiated |
0.74 (0.32–1.69) |
0.74 (0.30–1.84) |
0.52 |
1.58 (0.92–2.72) |
1.50 (0.81–2.81) |
0.20 |
|
Treatment | ||||||
| Surgery | 1 | 1 | 1 | 1 | ||
| Radiotherapy | 1.51 (0.55–4.15) | 1.01 (0.30–3.36) | 0.99 | 1.64 (0.87–3.12) | 1.50 (0.70–3.22) | 0.30 |
| Chemoradiotherapy |
0.98 (0.42–2.31) |
1.02 (0.39–2.70) |
0.96 |
1.48 (0.76–2.88) |
1.18 (0.55–2.57) |
0.67 |
|
TIL status | ||||||
| TIL high | 1 | 1 | 1 | 1 | ||
| TIL moderate | 2.96 (1.11–7.89) | 2.47 (0.72–8.50) | 0.15 | 1.39 (0.55–3.48) | 1.59 (0.54–4.71) | 0.40 |
| TIL low |
5.67 (1.96–16.38) |
4.86 (1.34–17.60) |
0.02 |
1.71 (0.71–4.13) |
2.11 (0.73–6.16) |
0.17 |
|
EGFR | ||||||
| Negative | 1 | 1 | 1 | 1 | ||
| Positive | 1.65 (0.76–3.62) | 1.54 (0.63–3.74) | 0.34 | 0.99 (0.53–1.87) | 1.31 (0.61–2.83) | 0.49 |
Abbreviations: CI=confidence interval; HPV=human papillomavirus; HR=hazards ratio; OPSCC=oropharyngeal cancer; TIL=tumour-infiltrating lymphocyte.
a
Multivariate analysis adjusted for age, T stage, N stage, and smoking status. Patients with no treatment excluded from analysis.